Satellite Symposium descriptions will be added as the information is provided. Please check this page regularly for updated information. For a complete outline of the program, please visit the Program at a Glance page.
Click on the links below to be directed to specific days:
Friday, October 11
Satellite Symposium: Astellas
07:30 – 09:00 (1 hour 30 min)
Preparing for the future of prostate cancer: pharmacy supporting sustainability in oncology services
Chair:
Professor Rob Duncombe, Director of Pharmacy, The Christie NHS Foundation Trust
Speakers:
Jacqui Lyttle, Business Training Consultant, JSL Consulting and Associates Ltd
Professor Nicola Stoner, Consultant Cancer Pharmacist, Oxford University Hospitals NHS Foundation Trust
Gillian Barmack, Senior Cancer Care Pharmacist, Beatson Institute for Cancer Research
Dr Philip Camilleri, Consultant Clinical Oncologist, Oxford University Hospitals NHS Foundation Trust
This symposium, entitled ‘Preparing for the future of prostate cancer: pharmacy supporting sustainability in oncology services’ is designed to introduce alternative approaches to running oncology clinics and provide advice to pharmacists on implementing/enhancing these approaches. Emphasis will be placed on non-medical prescriber-led clinics and pharmacist-led oral clinics, highlighting their ability to support the sustainability of oncology services by alleviating pressures in healthcare systems and optimising patient experience.
Satellite Symposium: BD
Finding the invisible threat: monitoring for hazardous drug surface contamination
Speakers:
Ryan Forrey, Senior Manager, Market Development for Hazardous Drug Safety, BD, United States
Paul Sessink, Managing Director, Exposure Control Sweden AB, Sweden
Nicholas Simon, Professor of Clinical Pharmacy, University of Lille; Hospital Pharmacist, Lille University Hospital, France
Jerry Siegel, Consultant, Safe Medication Management Associates, Inc. (SMMA), United States
There has been an increased focus on hazardous drug (HD) contamination. However, the implementation of HD surface contamination monitoring may be challenging. Current guidelines recommend surface wipe sampling, but do not yet require monitoring to be performed routinely. During this symposium, we will review a surface wipe sampling plan. Case studies will highlight best practices and technologies for detecting and managing HD surface contamination to protect healthcare workers and patients. There will be time for questions. Join BD in the Cremant room on Friday, 11th October from 12:30 to 14:00.
Satellite Symposium: BMS
Reducing Time to Treatment Administration (RTTA)
Speakers:
Dr Beth Lambourne, Consultant Medical Oncologist, Northern Centre for Cancer Care
James Richardson, Senior Clinical Pharmacist, Northern Centre for Cancer Care
Bristol-Myer Squibb Pharmaceutical Ltd (BMS) and the Northern Centre for Cancer Care (NCCC) at Newcastle-upon-Tyne Hospitals NHS Trust (NuTH) have been working collaboratively since March 2018. There have been two projects looking at Reducing Time to Treatment Administration – while the first project had a broad remit of looking at the complete patient pathway from the clinicians Decision to Treat to the patient receiving their first treatment the second project focused in on improving Treatment Efficiencies to reduce waiting times and improve patient experience. The symposium will initially focus on how the partnership was project managed before moving towards an interactive workshop where delegates can share their own experiences and look at how lessons learned can be replicated across their own areas of work.
Saturday, October 12
Satellite Symposium: MSD
07:00 – 08:30 (1 hour 30 min)
A Pharmacy perspective: Implementing 6 weekly dosing (Q6W) for KEYTRUDA®▼ (pembrolizumab) for single-agent indications
Speakers:
Professor Rob Duncombe, Director of Pharmacy, The Christie NHS Foundation Trust, Manchester, UK
Mr Brendan O’Sullivan, Lead Pharmacist, Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Following the recent license indication for Q6W dosing of pembrolizumab, across all monotherapy indications, this session will explore the science involved and analyse the relevant data for the modelling process. There will also be first-hand experience from a Pharmacist who has gone through the process of implementing the new dosing regimen in their centre, to raise awareness of the practical considerations, challenges and benefits.
Satellite Symposium: Gilead
CAR-T and Pharma-C
12:30 – 14:00 (1 hour 30 min)
Speakers:
Raakhee Shah, Lead Pharmacist Haematology, University College London Hospital, London, UK
Jackie Chappell, Consultant Pharmacist, Haematology/ATMPs, Kings College Hospital, London, UK
Prof Jérôme Larghero, Director of the Meary Cell and Gene Center and of the Department of Biotherapies, Hôpital Saint-Louis, Paris, France
The ISOPP Kite Cell Therapy symposium aims to provide an introduction to the science of CAR T cell therapy in DLBCL and PMBCL after 2 or more lines of systemic therapy, highlighting the role of the pharmacist in the procurement, storage and dispensing of these therapies. The symposium will provide guidance for pharmacists on how to set up a CAR T service and will explore the role of the pharmacist in the management of acute and chronic toxicities.
Satellite Symposium: Jazz
17:00 – 18:00 (1 hour)
Chemotherapy reimagined:improving outcomes in high-risk AML*
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Chair:
Mr Simon Cheesman, University College London Hospital NHS Foundation Trust, London, UK
Speakers:
Mr Simon Cheesman, University College London Hospital NHS Foundation Trust, London, UK
Dr Donal McLornan, Guy's and St Thomas’ NHS Foundation Trust, London, UK
This Jazz Pharmaceuticals evening symposium, taking place on Saturday 12 October 2019 at 17.00–18.00, will focus on the management of high-risk AML patients. Specifically, the principles behind combination chemotherapy, and synergy will be considered. The rationale and clinical development of Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion (daunorubicin and cytarabine) will then be discussed. A clinical case study of a patient treated with Vyxeos will illustrate the translation of the science into clinical practice, supported by safety and efficacy data from the pivotal Phase 3 trial. Finally, practical considerations for the pharmacist around managing patients with high-risk AML will be covered, including the availability, dosing and administration of Vyxeos, as well as considerations for other treatment regimens. We hope you will join us for what promises to be an exciting educational symposium.
This promotional symposium is organised and funded by Jazz Pharmaceuticals. Prescribing information (PI) for Vyxeos® liposomal 44mg/100mg powder for concentrate for solution for infusion (daunorubicin and cytarabine) and adverse event reporting instructions are available here. The PI will also be available upon request during the symposium and at the Jazz Pharmaceuticals exhibition stand.
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system.
In the United Kingdom: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765
Date of preparation: September 2019
Job code: EURW-INTVYX-0080h
Sunday, October 13
Satellite Symposium / Biosimilars Showcase: Amgen
13:00 – 14:30 (1 hour 30 min)
Biosimilars in practice – optimising implementation and maintaining patient care
Speakers:
Dr Gunar Stemer, Deputy Chief Pharmacist, Vienna General Hospital, Vienna, Austria
Ms Emma Foreman, Consultant Pharmacist, The Royal Marsden NHS Foundation Trust, London, UK
Professor, Robert Duncombe, Director of Pharmacy, The Christie NHS Foundation Trust, Manchester, UK
Biosimilars have the potential to contribute to the sustainability of healthcare systems. Therefore it is important for hospital pharmacists to have confidence in biosimilar quality and be aware of strategies for successful implementation. There are also practical considerations associated with the introduction of biosimilars, such as pharmacovigilance and informing patients about their treatment.
The symposium ‘Biosimilars in practice – optimising implementation and maintaining patient care’ will explore these topics, together with the key role of pharmacists in addressing potential barriers to biosimilar uptake and supporting multidisciplinary team education.
Virtual Preview: Pfizer Oncology
Introducing a new series of educational films for people living with breast cancer
Visit the Virtual Site Visit Room (Mouton Cadet) during the following times:
- Friday, October 11 at 15:30-15:45 (15 min)
- Saturday, October 12 at 16:00-16:15 (15 min)
- Sunday, October 13 at 08:30-08:45 (15 min)
Working with the oncology team from the Royal United Hospitals in Bath, Pfizer Oncology has created a series of 23 films designed to support and inform people living with primary and secondary breast cancer. The films draw on conversations with a group of men and women at various stages in the breast cancer journey allowing viewers to hear them share their personal perspective alongside members of the Bath oncology team who provide insight to the types of treatments, therapies and clinic experiences that a breast cancer patient could expect. Topics cover the practicalities of treatment, the type of support and interaction offered by the breast cancer team and more personal and emotional considerations regarding relationships, family and work. Launching in the UK in November 2019.
Pfizer Ltd. are a Corporate Sponsor of ISOPP 2019
PP-ONC-GBR-1146 Date of Prep October 2019